Trial Profile
An Open-Label, Randomized, Single-Dose, Three-Period, Three-Treatment Crossover Study Assessing the Effect of Food on the Bioavailability of a Single 60-mg Dose of a Novel Extended-Release Methylphenidate Orally Disintegrating Tablet Formulation(MPH XR-ODT) in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jan 2018
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- 23 Jan 2018 New trial record
- 25 May 2017 Results assessing the effect of food on the bioavailability of a single 60-mg dose of a novel extended-release methylphenidate orally disintegrating tablet formulation from the 2 periods of the fed/fasted comparison, published in the Clinical Pharmacology in Drug Development Journal.